Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.

We deliver a comprehensive view of your patients through our tissue and liquid tests, DNA and RNA sequencing, somatic and germline tests, tumor-normal matched profiling, and MRD and monitoring test options.

Tempus can help physicians & healthcare providers make more informed treatment decisions, and provides opportunities for research collaborations. Learn more.

Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."

Tempus Unlimited exists to provide a continuum of community based services that support the efforts of children and adults with disabilities to live as independently as possible in the least restrictive environment.

Find the latest Tempus AI, Inc. (TEM) stock quote, history, news and other vital information to help you with your stock trading and investing.

Get the latest Tempus AI Inc (TEM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

21 hours ago · Tempus AI has a $59.6 consensus price target from 11 analysts, ranging from $44 to $74. The latest ratings from TD Cowen, Loop Capital, and Needham imply an average target of $60.67, suggesting an ...

Shares of the Chicago, IL-based healthcare technology company focused on adopting artificial intelligence (AI) to advance precision medicine and patient care have plunged 28.9% in the past three...

Jan 13, 2025 · CHICAGO -- (BUSINESS WIRE)--Jan. 13, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.